{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:33:02Z","timestamp":1770485582847,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T00:00:00Z","timestamp":1375142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mundipharma International Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For patients with advanced indolent non-Hodgkin's lymphoma (NHL) or elderly patients with mantle cell lymphoma (MCL), the recently reported results of the German StiL NHL-1 2003 and the international BRIGHT phase III trials showed that, as first-line treatment, the combination of bendamustine and rituximab is at least as effective as rituximab\/cyclophosphamide\/doxorubicin\/vincristine\/prednisone or rituximab\/cyclophosphamide\/vincristine\/prednisone, possibly with a better therapeutic index. Bendamustine is therefore increasingly used in clinical practice. Because bendamustine has been used for many years in Germany and in Switzerland, our institutions have had extensive experience with bendamustine, both as a single agent and in combination with rituximab. In this comprehensive review, we summarize the most important clinical data from phase II\/III trials with bendamustine in patients with indolent NHL and MCL, both in the relapsed\/refractory setting and in the first-line setting. In addition, this review provides practical advice on how to optimally manage bendamustine therapy in patients with NHL.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0079","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T02:26:08Z","timestamp":1375237568000},"page":"954-964","source":"Crossref","is-referenced-by-count":24,"title":["Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management"],"prefix":"10.1093","volume":"18","author":[{"given":"Wolfram","family":"Brugger","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, and Palliative Care, Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,7,30]]},"reference":[{"key":"2021122308370136800_B1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2012.47.7315","article-title":"Selection of first-line therapy for advanced follicular lymphoma","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B2","volume-title":"NCCN guidelines lymphoma, version 1.2013","author":"National Comprehensive Cancer Network."},{"key":"2021122308370136800_B3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: First report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122308370136800_B4","first-page":"89","article-title":"Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study","volume":"22","author":"Morschhauser","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308370136800_B5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treament for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2021122308370136800_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.902.902","volume-title":"An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study","author":"Flinn","year":"2012"},{"key":"2021122308370136800_B7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.155.155","volume-title":"Differences in quality of life between bendamustine plus rituximab compared with standard first-line treatments in patients with previously untreated advanced indolent non-Hodgkin's lymphoma or mantle cell lymphoma","author":"Burke","year":"2012"},{"key":"2021122308370136800_B8","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: Rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2021122308370136800_B9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2011.03.002","article-title":"Bendamustine: Rescue of an effective antineoplastic agent from the mid-twentieth century","volume":"48","author":"Leoni","year":"2011","journal-title":"Semin Hematol"},{"key":"2021122308370136800_B10","volume-title":"Drug approval package: Treanda","author":"U.S. Food and Drug Administration."},{"key":"2021122308370136800_B11","volume-title":"Levact","author":"European Medicines Agency.","year":"2013"},{"key":"2021122308370136800_B12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"2021122308370136800_B13","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B14","volume-title":"Product information","author":"Swissmedic.","year":"2013"},{"key":"2021122308370136800_B15","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B16","volume-title":"Blood","author":"Rummel","year":"2010"},{"key":"2021122308370136800_B17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3747\/co.19.1064","article-title":"A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"19","author":"Van der Jagt","year":"2012","journal-title":"Curr Oncol"},{"key":"2021122308370136800_B18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrclinonc.2012.107","article-title":"From ASCO\u2013lymphoma: Bendamustine and rituximab triumphs as first-line therapy","volume":"9","author":"Research Highlight","year":"2012","journal-title":"Nature Reviews Clinical Oncology"},{"key":"2021122308370136800_B19","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B20","volume-title":"ClinicalTrials.gov","author":"U.S. National Institutes of Health.","year":"2013"},{"key":"2021122308370136800_B21","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B22","volume-title":"Combinations of the phosphatidylinositol 3-kinase-delta (PI3Kd) inhibitor GS1101 (CAL-101) with rituximab and\/or bendamustine are tolerable and highly active in previously treated, indolent Non-Hodgkin lymphoma: Results from a phase I study","author":"Fowler","year":"2012"},{"key":"2021122308370136800_B23","volume-title":"A phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","author":"Blum","year":"2012"},{"key":"2021122308370136800_B24","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","article-title":"Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel","volume":"10","author":"Cheson","year":"2010","journal-title":"Review Clin Lymphoma Myeloma Leuk"},{"key":"2021122308370136800_B26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/11531550-000000000-00000","article-title":"Non-Hodgkin's lymphoma in the elderly","volume":"27","author":"Caimi","year":"2010","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"2021122308370136800_B27","article-title":"Pharmacokinetics and toxicity profile of bendamustine in myeloma patients with end-stage renal disease","volume":"4","author":"Preiss","year":"2003","journal-title":"Hematol J"},{"key":"2021122308370136800_B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D385N6C9JF","article-title":"Severe cutaneous interface drug eruption associated with bendamustine","volume":"16","author":"Alamdari","year":"2010","journal-title":"Dermatol Online J"},{"key":"2021122308370136800_B29","volume-title":"Treanda: Highlights of prescribing information","author":"Cephalon."},{"key":"2021122308370136800_B30","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1345\/aph.1M329","article-title":"Bendamustine-associated hemolytic anemia","volume":"11","author":"Glance","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2021122308370136800_B31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/107327481201900309","article-title":"Optimizing premedications in the prevention of bendamustine infusion-related reactions","volume":"3","author":"Tombleson","year":"2012","journal-title":"Cancer Control"},{"key":"2021122308370136800_B32","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.leukres.2011.07.014","article-title":"Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma","volume":"35","author":"Carter","year":"2011","journal-title":"Leuk Res"},{"key":"2021122308370136800_B33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-012-1050-9","article-title":"HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine","volume":"95","author":"Tsutsumi","year":"2012","journal-title":"Int J Hematol"},{"key":"2021122308370136800_B34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-011-1307-z","article-title":"Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine","volume":"91","author":"Lim","year":"2011","journal-title":"Ann Hematol"},{"key":"2021122308370136800_B35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","article-title":"Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumours","volume":"11","author":"Sch\u00f6ffski","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122308370136800_B36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study","volume":"10:26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CLML.2010.n.079","article-title":"Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma","volume":"10","author":"Cheson","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122308370136800_B38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5144\/1658-3876.2011.157","article-title":"Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect","volume":"4","author":"Malipatil","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2021122308370136800_B39","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","article-title":"Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma","volume":"66","author":"Owen","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308370136800_B40","article-title":"Retreatment with bendamustine-containing regimens in patients with relapsed\/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions","author":"Weide","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2021122308370136800_B41","volume-title":"Blood","author":"Burchardt","year":"2009"},{"key":"2021122308370136800_B42","volume-title":"Bendamustine-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstr\u00f6m's macroglobulinemia: Results from a prospective, randomized, multicenter study (StiL NHL 7-2008 \u2013 MAINTAIN \u2013; ClinicalTrials.gov identifier","author":"Rummel","year":"2012"},{"key":"2021122308370136800_B43","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"2021122308370136800_B44","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"2021122308370136800_B45","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308370136800_B46","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/8\/954\/41857166\/oncolo_18_8_954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/8\/954\/41857166\/oncolo_18_8_954.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T18:43:45Z","timestamp":1715798625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/8\/954\/6410273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,30]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,7,30]]},"published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0079","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,8,1]]},"published":{"date-parts":[[2013,7,30]]}}}